COMMITTED TO CHANGING THE FACE OF CANCER TREATMENT
The BioCanRx Board of Directors is responsible for ensuring financial accountability, scientific excellence, knowledge exchange and operational efficiency. The board approves policies and procedures consistent with the goals and mission of the network. It also determines the mandate, membership, authority and makeup of committees.
The Board provides leadership and direction to BioCanRx so that it remains on target with respect to its strategic plan and commitment to the NCE mandate.
MEMBERS OF THE BOARD:
 |
 |
 |
 |
| Ken Newport Chair, Board of Directors |
Dr. John Bell Scientific Director, BioCanRx Senior Scientist, The Ottawa Hospital Professor, uOttawa |
Ela Borenstein Program Director Business Development Bank of Canada (BDC) |
Dr. Josée Brisebois Head of Medical, Incyte Canada / Medical Affairs with oversight of Clinical & Regulatory Affairs |
 |
 |
 |
 |
| Craig Earle Vice-President, Cancer Control at the Canadian Partnership Against Cancer |
Karimah Es Sabar Chief Executive Officer & Partner, Quark Venture Inc. |
Doreen Hume Partner, Audit & Assurance, Deloitte Canada |
Debra Lynkowski Chief Operating Officer The Ottawa Hospital Research Institute |
 |
 |
 |
 |
| Antonia Palmer Co-Founder at Ac2orn: Advocacy for Canadian Childhood Oncology Research Network |
Dr. David Poon Vice President Business Development and Alliance Management, Zymeworks Inc. |
Dr. John Stagg Associate Professor, Faculty of Pharmacy at the University of Montreal Lab Head at the CHUM Hospital Research Centre |
Dr. Christine Williams Deputy Director, Ontario Institute for Cancer Research (OICR) |
 |
|||
| Russell Williams Senior Vice President, Mission, Diabetes Canada |
EX-OFFICIO MEMBERS (NON-VOTING)
 |
| Dr. Stéphanie Michaud President and CEO, BioCanRx Secretary, Board of Directors |
OBSERVERS
| NCE Liaison to be Announced |
